Insmed (INSM) Long-Term Debt Issuances (2012 - 2022)
Insmed (INSM) posted quarterly Long-Term Debt Issuances of $350.0 million for Q4 2022, down 11.39% quarter-over-quarter from $395.0 million in Q4 2018.
Powered by 
Analysis
Insmed (INSM) Long-Term Debt Issuances (2012 - 2022) Analysis & Trends
Insmed's Long-Term Debt Issuances history runs 4 years deep, the most recent figure standing at $350.0 million for Q4 2022.
- In Q4 2022, Long-Term Debt Issuances changed N/A year-over-year to $350.0 million; the TTM figure through Dec 2022 stood at $350.0 million (changed N/A YoY), while the FY2024 annual figure was $150.0 million, changed N/A from the prior year.
- Long-Term Debt Issuances for Q4 2022 stood at $350.0 million, down from $395.0 million in the prior quarter.
- The five-year high for Long-Term Debt Issuances was $450.0 million in Q1 2018, with the low at -$395.0 million in Q2 2018.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Debt Issuances (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Incyte | 25.44 Bn | 20.91 Bn | 1.57 Bn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2022 | 350.00 Mn |
| Mar 31, 2018 | 450.00 Mn |
| Dec 31, 2016 | 20.00 Mn |
| Dec 31, 2012 | 10.27 Mn |